We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.
A new study published by Dr. Kyu Rhee’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics.
Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. In this interview, Dr. Ojima discusses the work his lab has been doing on tri-substituted benzimidazole compounds that inhibit TB growth.
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. Its range and ability to inhibit multiple targets, makes SQ109 an attractive broad-based antimicrobial compound that also reduces the likelihood of resistance developing in bugs.
Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.
This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.
In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model.
HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort, Lucca (Barga), Italy.
This week we highlight a study out of Dr. William Jacobs, Jr.’s lab showing that “vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis.” Additional links to other news and articles related to TB R&D are included.